Home World News Ensartinib Improves DFS Outcomes in Patients with ALK-positive, Completely Resected Stage II to... World News Ensartinib Improves DFS Outcomes in Patients with ALK-positive, Completely Resected Stage II to IIIB NSCLC By Ogkologos - July 27, 2026 186 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ELEVATE study Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR Real-World Increase in Biomarker Testing in Lung Cancer Patients, Registry Study... March 23, 2022 Breast Cancer Survivor Driven from Her Home by Noxious Gases from... June 11, 2021 Adjuvant Atezolizumab Plus Bevacizumab Improves RFS Among Patients at High Risk... November 16, 2023 Hospice Service Provides “Bucket List” Tattoo for 77-Year-Old Woman with Breast... June 11, 2019 Load more HOT NEWS Using Immunotherapy to Treat Advanced Melanoma and Advanced Non-Small Cell Lung... Cómo puede ayudar la terapia del piso pélvico a las personas... How radiotherapy became a lifesaver – from X-rays to the proton... No Survival Benefit for Adding Adjuvant Chemotherapy to Endocrine Therapy in...
